Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Alzheimer Disease 10”

35 trials

Showing 20 of 35 results

Not applicableWithdrawnNCT04100889
What this trial is testing

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

Who this might be right for
Alzheimer DiseaseAlzheimer Disease 1Alzheimer Disease 2+20 more
ProgenaBiome
Post-approval studies (Phase 4)Study completedNCT00234637
What this trial is testing

Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment

Who this might be right for
Alzheimer's Disease
Novartis 204
Post-approval studies (Phase 4)Study completedNCT00731224
What this trial is testing

Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.

Who this might be right for
Alzheimer's Disease
Novartis Pharmaceuticals 380
Not applicableStudy completedNCT03534687
What this trial is testing

Exercise and the Receptor for Advanced Glycation End Products (RAGE)

Who this might be right for
Diabetes Mellitus, Type 2
University of Michigan 50
Large-scale testing (Phase 3)Ended earlyNCT01736579
What this trial is testing

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Who this might be right for
Alzheimer´s Disease
Baxalta now part of Shire 6
Post-approval studies (Phase 4)Study completedNCT00561392
What this trial is testing

Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Novartis 208
Early research (Phase 1)Ended earlyNCT01072812
What this trial is testing

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

Who this might be right for
Alzheimer's DiseaseAmnestic Mild Cognitive Impairment
Annovis Bio Inc. 5
Large-scale testing (Phase 3)Study completedNCT00818662
What this trial is testing

Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Who this might be right for
Alzheimer´s Disease
Baxalta now part of Shire 390
Large-scale testing (Phase 3)Study completedNCT01399125
What this trial is testing

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Novartis Pharmaceuticals 501
Large-scale testing (Phase 3)Study completedNCT00478205
What this trial is testing

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Eisai Inc. 1,467
Large-scale testing (Phase 3)Ended earlyNCT01524887
What this trial is testing

Phase 3 IGIV, 10% in Alzheimer´s Disease

Who this might be right for
Alzheimer´s Disease
Baxalta now part of Shire 508
Not applicableStudy completedNCT03212599
What this trial is testing

Disulfiram as a Modulator of Amyloid Precursor Protein-processing

Who this might be right for
Alcohol Addiction
Johannes Gutenberg University Mainz 17
Large-scale testing (Phase 3)Study completedNCT00506415
What this trial is testing

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

Who this might be right for
Alzheimer Disease
Novartis Pharmaceuticals 1,584
Testing effectiveness (Phase 2)Study completedNCT00141661
What this trial is testing

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Who this might be right for
Alzheimer Disease
Pfizer 67
Testing effectiveness (Phase 2)Study completedNCT00165659
What this trial is testing

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Who this might be right for
Alzheimer Disease
Eisai Limited
Large-scale testing (Phase 3)Study completedNCT02550665
What this trial is testing

Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg

Who this might be right for
Alzheimer's Disease
Asan Medical Center 176
Early research (Phase 1)Study completedNCT00494962
What this trial is testing

Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects

Who this might be right for
Alzheimer Disease
Wyeth is now a wholly owned subsidiary of Pfizer 40
Not applicableStudy completedNCT05808530
What this trial is testing

Cognitive Stimulation Therapy

Who this might be right for
Alzheimer Disease 10DementiaApathy+2 more
Hasan Kalyoncu University 56
Testing effectiveness (Phase 2)Study completedNCT00812565
What this trial is testing

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Octapharma 58
Testing effectiveness (Phase 2)Study completedNCT01300728
What this trial is testing

Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment

Who this might be right for
Mild Cognitive Impairment
Sutter Health 52
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation